- Home
- CGEM vs CHI Comparison
CGEM vs CHI Comparison
Compare CGEM & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGEM | CHI |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 1.0B |
| IPO Year | 2020 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CGEM | CHI |
|---|---|---|
| Price | $13.77 | $12.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $30.13 | N/A |
| AVG Volume (30 Days) | ★ 881.8K | 169.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $10.00 |
| 52 Week High | $16.74 | $12.70 |
Technical Indicators
Market Signals| Indicator | CGEM | CHI |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 59.12 |
| Support Level | $12.41 | $10.34 |
| Resistance Level | $16.21 | $12.70 |
| Average True Range (ATR) | 0.94 | 0.26 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 11.57 | 78.26 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.